All studies started from 2014 to 15 September 2022 were ‘Immunotherapy’, ‘Pembrolizumab’, ‘Atezolizumab’, ‘Dostarlimab’, ‘Durvalumab’,Īnd ‘Cemiplimab’. ‘Gynecological neoplasm’, ‘Ovarian cancer’, ‘Ovarian neoplasm’, ‘OvarianĬarcinoma’, ‘Endometrial cancer’, ‘Endometrial neoplasms’, ‘EndometrialĪdenocarcinoma’, ‘Uterine cervical cancer’, ‘uterine cervical neoplasm’ as search Search was carried out on, entering ‘Gynecological cancer’, Websites of the organisations MITO and MaNGO were consulted and an in-depth In order to obtain an accurate picture of the latest ongoing studies, the Is the most recent update in a constantly evolving framework. This review will discuss the current status of immunotherapy in gynaecologicalĬancers with particular attention to the Italian reality, which has been anĪctive part of research in this field for years, providing what to our knowledge Immunotherapy not only an important promise for the future but also a concreteĬurrent reality for thousands of women worldwide. Several studies haveĪlready led to the approval of new drugs by regulatory agencies, making Therapeutic strategies on which research is focusing. Gynaecological oncological malignancies, are now among the most promising Non-lasting response to conventional therapies of advanced or relapsed Immunotherapeutic treatments, in fact, in view of the generally poor or Recent years in gynaecological oncologic diseases. Oncologic diseases, the potential of immunotherapy is being investigated in Thanks to an ever-improving understanding of the role of the immune system in Protocols, known as PDTAs (Percorsi Diagnostico Terapeutici Assistenziali, Therapeutic process of gynaecological cancers through the creation of shared Working groups have also recentlyĮmerged at the regional level in order to standardize the diagnostic and Trials concerning gynaecological oncology. The Italian reference points for the main national and international clinical Two main cooperative groups, MITO (Multicenter Italian Trials in Ovarian cancerĪnd gynaecological malignancies) and MaNGO (Mario Negri Gynecologic Oncology) are Malignancies, more than half from ovarian carcinomas. 6000 Italian women lost their lives in 2020 due to these According to Associazione Italiana Registri Tumori (AIRTUM) 2020 data, more than 8000 new cases of endometrialĬarcinomas, 5000 new cases of ovarian carcinomas, and 2300 cervical carcinomas Gynaecological cancers represent a major global burden, and the same is true for Important promise for the future but also a concrete current reality for Conclusions: Several trials have led to the approval of new drugs by regulatory agencies in gynaecological oncology, making immunotherapy not only an Results are already in the clinical management of advanced disease. Seems to be one of the most interesting settings for immunotherapy and some The results of further trials are now expected. Immunotherapy in OC has been a complex challenge for years,Īs early trials have shown. The identification of newīiomarkers will make it possible to select patients who can best benefit from Of immunotherapy in today’s treatment pathways. Impact of immunotherapy has been considerable, as demonstrated by the inclusion The widest participation of Italian centers have been presented. Terms of PFS (Progression Free Survival) and adverse events reported, and with Findings in Brief: The studies with the greatest clinical impact, specifically in Monoclonal antibodies, immuneĬheckpoint inhibitors and drug-conjugated antibodies (ADCs) therapies wereĬonsidered. To September 2022 were included in the search. Italian Trials in Ovarian cancer (MITO) and Mario Negri Gynecologic Oncology (MaNGO) groups were consulted and an in-depth search was carried out on. (CC) cancers with particular attention to the Italian reality. This review will discuss theĬurrent status of immunotherapy in endometrial (EC), ovarian (OC) and cervical Malignancies is being investigated in recent years. Objective: The potential of immunotherapy in gynaecological
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |